Silicon Canals
TRENDING
  • Mobility
  • AI
  • FinTech
  • Software & SaaS
No Result
View All Result
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Features
    • How-to
    • Knowledge & Insights
    • Guest Contributions
  • Partners
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Scaling-up in Europe
    • Blue Tulip Awards
    • Partner with us
    • Promoted content
  • Events
    • Technology Events in Europe
    • Submit your event
  • Jobs
  • About us
    • Partner with us
    • About
    • Team
    • Newsletter
  • Contact
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Features
    • How-to
    • Knowledge & Insights
    • Guest Contributions
  • Partners
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Scaling-up in Europe
    • Blue Tulip Awards
    • Partner with us
    • Promoted content
  • Events
    • Technology Events in Europe
    • Submit your event
  • Jobs
  • About us
    • Partner with us
    • About
    • Team
    • Newsletter
  • Contact
No Result
View All Result
Silicon Canals
No Result
View All Result

This Belgian-French biotech startup secures €20M funding to cure lung cancer completely

Editorial team by Editorial team
January 23, 2020
in News, (Crowd)funding, Startups
These 10 European tech startups want to help you improve your mental fitness
76
SHARES
LinkedInTwitterWhatsAppFacebook

PDC*line Pharma is a Belgian-French a clinical-stage biotech startup developing a new class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) loaded with peptides derived from target tumour antigens. Founded in 2014 as a spin-off of the French Blood Bank, this startup comprises a team of skilled professionals based in Grenoble (France) and Liège (Belgium).

PDC*line Pharma focuses on lung cancer with a new candidate in phase 1b/2 clinical trial and neoantigens. The objectives of phase I/II study are to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate, PDC*lung01.

- Partner content -
digital skills dutch workforce
Salesforce’s report on Dutch workforce’s digital skills
Has the Dutch workforce mastered all digital skills? Find out
Has the Dutch workforce mastered all digital skills? Find out Show Less
Read more

Secures €20M funding

Now, PDC*line Pharma has raised €20 million Series B funding. This funding has come almost two and a half years after its previous funding round that took place in 2017. PDC*line Pharma has raised the investment from five new investors such as Korean Investment Partners, the leading multi-billion dollar South-Korean fund, two further South-Korean funds, Shinhan-Cognitive Start-up Fund and UTC 2019 BIOVENTUREFUND, as well as two Belgian funds, SRIW (The Regional Investment Company of Wallonia) and Sambrinvest (the investment fund of Charleroi).

These join the existing investors such a Sambrinvest (the investment fund of Charleroi). They join the company’s historical investors: SFPI-FPIM, the Belgian Federal Holding and Investment Company, Noshaq Group (ex-Meusinvest), the Financière Spin-off Luxembourgeoise/INVESTSUD Group and a group of international business angels and well-known entrepreneurs.

Develops lung cancer vaccine!

PDC*lung01 comprises PDCline professional antigen-presenting cells loaded with HLA-A2 restricted peptides derived from six shared tumour antigens. PDC*line Pharma focuses on the development of PDC*lung01, a candidate for non-small-cell lung cancer (NSCLC) currently in phase I/II, and PDC*neo with neoantigens in preclinical development. In March 2019, the PDC*line Pharma granted an exclusive license to the LG Chem Life Sciences company in South Korea and an exclusive option in other Asian countries for the development and commercialisation of the PDC*lung01 cancer vaccine for lung cancer.

According to François Fontaine, general advisor to PDC*line Pharma at SFPI-FPIM, “PDC*line Pharma’s cancer vaccine platform is both highly innovative and meets an important medical need. It also has a clear societal impact for the Liège region, for Belgium and beyond. We welcome the continued strong support of the Walloon region and the new funding by existing and new investors.”

Main image picture credits: PDC*line Pharma

Stay tuned to Silicon Canals for more European technology news.

 - Partner content -
How cybersecurity scaleup Intigriti conquered the world?
How cybersecurity scaleup Intigriti conquered the world?
Catch our interview with Paul Down, Head of Sales at Intigriti.
Catch our interview with Paul Down, Head of Sales at Intigriti. Show Less
Read more
Tags: fundingstartups
Share4Tweet14SendShare42

Featured events

Current Month

may

28apr(apr 28)12:1331may(may 31)12:13FeaturedApplications for Techleap.nl’s Rise Batch 8 are open now

Techleap

Event Details

Are you an ambitious scaleup operating out of the Netherlands? Accelerate your growth with Techleap.nl’s Rise programme. Join their Batch #8!

Event Details

Are you an ambitious scaleup operating out of the Netherlands? Accelerate your growth with Techleap.nl’s Rise programme. Join their Batch #8!

Rise is an exclusive programme for serious tech players. In a trusted environment, scaleup founders share and discuss their growth challenges during tailor-made sessions with experienced entrepreneurs and scaling experts. Every quarter we select 10 companies to join the programme. It’s free, and we don’t seek equity. Check now if your company is eligible!

About Techleap

Techleap.nl’s programmes connect founders with scaling icons, industry experts and fellow tech entrepreneurs. It’s your chance to share challenges and hurdles with peers and established CEOs, and as a result, create favourable growth conditions for your business and overcome looming obstacles on your entrepreneurial path.

If you have any questions about the programme or the application process, please contact the Rise Batch Manager – Peter-Jan Kok at [email protected].

Apply here.

more

Time

April 28 (Thursday) 12:13 - May 31 (Tuesday) 12:13

Learn More

CalendarGoogleCal

june

Taets Art and Events ParkHemskade 16, 1506 PR Zaandam

16junAll Day17FeaturedTNW Conference

Event Details

Join TNW Conference in Amsterdam on June 16 & 17 to all you need to know about the latest market killers and breakout tech, connect with the industry’s who’s-who, and

Event Details

Join TNW Conference in Amsterdam on June 16 & 17 to all you need to know about the latest market killers and breakout tech, connect with the industry’s who’s-who, and turn your business meetings upside down on our ferris wheel… With endless networking opportunities, the world’s boldest voices, and unrivaled party vibes, this year’s TNW Conference will be off the charts!

Time

june 16 (Thursday) - 17 (Friday)

Location

Taets Art and Events Park

Hemskade 16, 1506 PR Zaandam

Learn More

CalendarGoogleCal

Partner content | Work with us

European Startups can expand to Asia through the South Korean Government’s K-Startup Grand Challenge

Running a small business? These 5 tips can create a domino effect of productivity across your entire company

Triller acquires Dutch DJ Sam Feldt’s Fangage to expand its platform for creators

Sweden’s Gimi partners with Dutch bank ABN AMRO to help young people manage and understand their finances

Calling all startups aiming to test their mobility innovations in the real world: Mobility Lab 2022 registration is now open

Silicon Canals | Jobs


Breaking news from Amsterdam | Partner

Amsterdam’s SingularityNET and its spin-off project SingularityDAO sign a €23.6M capital commitment

Amsterdam’s The Social Handshake raises €1.1M to help employees support charities directly from their salaries

These 9 European AI and HPC startups are selected for EscherCloud and NVIDIA’s Hyperion Lab

Amsterdam’s Timberhub raises €1.5M led by Speedinvest to digitise the timber trade

  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy Policy
  • Cookie Policy (UK)
  • Cookie Policy (EU)
  • Terms & Conditions Silicon Canals

Silicon Canals 2014-2022 | Website: Bright Idiots

No Result
View All Result
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Features
    • How-to
    • Knowledge & Insights
    • Guest Contributions
  • Partners
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Scaling-up in Europe
    • Blue Tulip Awards
    • Partner with us
    • Promoted content
  • Events
    • Technology Events in Europe
    • Submit your event
  • Jobs
  • About us
    • Partner with us
    • About
    • Team
    • Newsletter
  • Contact

Silicon Canals 2014-2022 | Website: Bright Idiots

Stay updated with the Silicon Canals daily and weekly newsletters.
We promise we won't spam you. You can choose to unsubscribe anytime.
Stay updated with the Silicon Canals daily and weekly newsletters.
We promise we won't spam you. You can choose to unsubscribe anytime.
Silicon Canals
Manage your privacy

To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Statistics

Marketing

Features
Always active

Always active
Manage options Manage services Manage vendors Read more about these purposes
Manage options
{title} {title} {title}
X
X